Eosinophilic Gastroenteritis Epidemiology

Eosinophilic Gastroenteritis Trends

• The patient burden of eosinophilic gastroenteritis may remain underestimated due to delayed diagnosis, nonspecific symptom presentation, and the lack of universally standardized diagnostic criteria, indicating potential opportunity for further expansion of the diagnosed patient population during the forecast period.
• In 2022, Eosinophilic Gastroenteritis has an estimated prevalence of 5.1 per 100,000 in the United States and belongs to the spectrum of eosinophilic gastrointestinal disorders, alongside eosinophilic esophagitis and eosinophilic colitis. 
• The disease shows a male predominance, with men representing a greater proportion of diagnosed cases as compared to females. 
• The mucosal subtype accounts for the majority (50–100%) of diagnosed eosinophilic gastroenteritis cases, followed by muscularis (10–30%) and subserosal (10–15%) subtypes.
• According to National Organization for Rare Disorders (NORD), Eosinophilic Gastroenteritis predominantly affects children and adults aged 20–50 years.
• In 2020, the prevalence of eosinophilic gastroenteritis in Japan was reported to be higher as compared to eosinophilic esophagitis (EoE).

Eosinophilic Gastroenteritis Epidemiology Forecast in the United States

• 2025 Prevalent Cases of Eosinophilic Gastroenteritis: ~XX Cases
• Eosinophilic Gastroenteritis  Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Eosinophilic Gastroenteritis  – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Eosinophilic Gastroenteritis , historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Eosinophilic Gastroenteritis Understanding and Diagnosis Algorithm

Eosinophilic Gastroenteritis Overview and Diagnosis

Eosinophilic Gastroenteritis Overview and Diagnosis

Eosinophilic gastroenteritis is a rare, chronic inflammatory gastrointestinal disorder characterized by eosinophilic infiltration of the gastrointestinal tract in the absence of secondary causes of eosinophilia such as parasitic infections, malignancies, or systemic inflammatory disorders. The disease can affect multiple layers of the gastrointestinal wall, including the mucosal, muscular, and serosal layers, leading to heterogeneous clinical manifestations depending on the site and depth of involvement. It is considered part of the broader spectrum of eosinophilic gastrointestinal diseases (EGIDs) and is frequently associated with allergic conditions including asthma, food allergies, eczema, and other atopic disorders. Clinical manifestations vary widely and commonly include abdominal pain, nausea, vomiting, diarrhea, bloating, weight loss, anemia, gastrointestinal bleeding, and nutritional deficiencies, often resulting in substantial quality-of-life impairment.

Further details are provided in the report.

Eosinophilic Gastroenteritis Diagnosis

Diagnosis of eosinophilic gastroenteritis remains challenging due to its nonspecific presentation and clinical overlap with multiple gastrointestinal disorders. Diagnosis generally begins with comprehensive clinical assessment, symptom evaluation, laboratory investigations, and exclusion of secondary causes of eosinophilia. Endoscopy with multiple gastrointestinal biopsies remains the cornerstone of diagnosis, allowing histopathological identification of abnormal eosinophilic infiltration within gastrointestinal tissues. Additional diagnostic tools including complete blood count with eosinophil evaluation, serum immunoglobulin E (IgE) assessment, allergy testing, imaging studies, and endoscopic evaluation may support disease characterization. Early and accurate diagnosis is critical to minimize delays in treatment, reduce complications, and support selection of appropriate targeted therapeutic strategies.

Further details are provided in the report.

Eosinophilic Gastroenteritis Epidemiology

Key Findings from Eosinophilic Gastroenteritis Epidemiological Analysis and Forecast 

• The prevalence of eosinophilic gastroenteritis is increasing globally, primarily driven by improved recognition of EGIDs, increasing physician awareness, advancement endoscopic and histopathological diagnostic approaches, and broader identification of previously underdiagnosed patients, and increasing prevalence of allergic and atopic disorders.
• The United States accounts for a highest number of diagnosed eosinophilic gastroenteritis cases across the 7MM due to higher disease awareness, access to specialist gastroenterology care, and increasing use of endoscopy with biopsy-based diagnostic evaluation.
• Eosinophilic gastroenteritis frequently affects younger and middle-aged adults, although disease can occur across all age groups. 
• Eosinophilic gastroenteritis shows a male predominance, with men representing a greater proportion of diagnosed cases as compared to females. 
• The mucosal subtype accounts for the majority (50–100%) of diagnosed eosinophilic gastroenteritis cases, followed by muscularis (10%–30%) and subserosal (10%–15%) subtypes.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of Eosinophilic Gastroenteritis, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Eosinophilic Gastroenteritis Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Eosinophilic Gastroenteritis? What will be the growth opportunities across the 7MM concerning the patient population with Eosinophilic Gastroenteritis?
• What is the historical and forecasted Eosinophilic Gastroenteritis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.